Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.31
- Piotroski Score 4.00
- Grade Outperform
- Symbol (TRDA)
- Company Entrada Therapeutics, Inc.
- Price $18.10
- Changes Percentage (0.95%)
- Change $0.17
- Day Low $17.70
- Day High $18.40
- Year High $20.49
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $20.00
- High Stock Price Target $20.00
- Low Stock Price Target $20.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.69
- Trailing P/E Ratio 22.81
- Forward P/E Ratio 22.81
- P/E Growth 22.81
- Net Income $-6,685,000
Income Statement
Quarterly
Annual
Latest News of TRDA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Forecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved Drastically
Analysts have significantly upgraded revenue estimates for Entrada Therapeutics (NASDAQ:TRDA), leading to a surge in stock price. Despite concerns of revenue decline in 2024, the company is expected t...
By Yahoo! Finance | 3 months ago -
With 40% ownership, Entrada Therapeutics, Inc. (NASDAQ:TRDA) has piqued the interest of institutional investors
Five investors collectively own a majority stake of 55% in Entrada Therapeutics, Inc. Institutions hold the largest share at 40%, followed by hedge funds and insiders. This ownership structure influen...
By Yahoo! Finance | 4 months ago
